MiNK Therapeutics

INKT Rare disease Lead: Phase 2 ★ Read the deep dive → 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Catalyst timeline

agenT-797 GEJ readout2026agenT-797 GEJ readout, 2026, material
agenT-797 GvHD prevention trial startMid-2026agenT-797 GvHD prevention trial start, Mid-2026, notable
agenT-797 topline2H 2026agenT-797 topline, 2H 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

agenT-797

Cell Target: CD1d, iNKT

Acute Respiratory Distress Syndrome Phase 2 NCT04582201
Solid Tumors Phase 1 NCT05108623
Gastric Cancer Phase 2 Memorial Sloan Kettering Cancer Center
Graft-Versus-Host Disease Phase 1 University of Wisconsin–Madison

MiNK-413

Cell Target: BCMA

Undisclosed indication Preclinical

MiNK-215

Cell Target: FAP

Colorectal Cancer Preclinical

PRAME-iNKT

Cell Target: PRAME

Undisclosed indication Preclinical C-Further

Technology platforms

CARDIS

Hybrid phage and mammalian display technology enabling highly selective and functionally optimized CAR, TCR, and bispecific engager discovery. Designed to produce candidates with improved pharmaceutical quality, minimal off-target toxicity, and reduced immunogenic risk through fully human antibody fragments. Applied to iNKT cell engineering for oncology and immune-mediated diseases.

Biotech Distilled coverage (2)

2026-08-07 UPDATE: MiNK Therapeutics (INKT) - The First Patients Are Alive 🔒 Paid
2026-06-13 MiNK Therapeutics (INKT) - Scientific Deep Dive for agenT-797 and the iNKT Cell Pipeline

Articles open on Substack. Some deep dives are subscriber-only.